{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:27:54Z","timestamp":1787495274134,"version":"build-2736575974"},"reference-count":47,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Background\/Objective: Neurofilament light chain (Nf-L), neurofilament heavy chain (Nf-H), and chitinase 3-like 1 (CHI3L1) are cerebrospinal fluid (CSF) biomarkers of neuroaxonal damage and inflammation in multiple sclerosis (MS). Their longitudinal response to disease-modifying therapies and association with clinical and radiological outcomes remain incompletely understood. The aim of this study is to evaluate the impact of interferon beta (IFN-\u03b2) therapy on CSF levels of Nf-L, Nf-H, and CHI3L1 in early relapsing\u2013remitting MS (RRMS) and assess their association with long-term clinical outcomes and MRI activity. Methods: We conducted a prospective two-year observational study involving 14 treatment-naive RRMS patients who initiated IFN-\u03b2 therapy. CSF levels of Nf-L, Nf-H, and CHI3L1 were measured at baseline and after two years. Clinical disability was assessed via the Expanded Disability Status Scale (EDSS) and by studying brain MRI activity. A 15-year clinical follow-up was performed for 12 patients. Results: Nf-L levels significantly decreased after two years of IFN-\u03b2 treatment (p = 0.039), while CHI3L1 levels significantly increased (p = 0.001). Nf-H levels remained stable. Nf-L and CHI3L1 levels at baseline and follow-up correlated with relapse rate and long-term EDSS. Nf-H levels correlated with EDSS scores but not with relapse or MRI activity. A trend toward a positive correlation between increasing Nf-L levels and MRI activity was observed (p = 0.07). Conclusions: CSF biomarkers demonstrate differential responses to IFN-\u03b2 therapy in early RRMS. Nf-L emerges as a sensitive biomarker of treatment response and disease activity, while CHI3L1 may reflect ongoing tissue remodeling and inflammation. These findings support the utility of CSF biomarker monitoring for personalized treatment strategies in MS.<\/jats:p>","DOI":"10.3390\/biomedicines13061394","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T03:52:28Z","timestamp":1749181948000},"page":"1394","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Longitudinal Changes in Neuroaxonal and Inflammatory CSF Biomarkers in Multiple Sclerosis Patients Undergoing Interferon Beta Therapy"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5282-8905","authenticated-orcid":false,"given":"Simona","family":"Petrescu","sequence":"first","affiliation":[{"name":"Department of Neurology, Elias Emergency and University Hospital, 011461 Bucharest, Romania"},{"name":"Department of Clinical Neurosciences, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7682-7030","authenticated-orcid":false,"given":"Maria-Melania","family":"Dumitru-Martoiu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Elias Emergency and University Hospital, 011461 Bucharest, Romania"},{"name":"Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford OX3 9DU, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina Aura","family":"Panea","sequence":"additional","affiliation":[{"name":"Department of Neurology, Elias Emergency and University Hospital, 011461 Bucharest, Romania"},{"name":"Department of Clinical Neurosciences, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4061-0837","authenticated-orcid":false,"given":"Charlotte E.","family":"Teunissen","sequence":"additional","affiliation":[{"name":"Neurology Laboratory and Biobank, Department of Clinical Chemistry, VU University Medical Center, 1081 HV Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"a028936","DOI":"10.1101\/cshperspect.a028936","article-title":"Multiple sclerosis pathology","volume":"8","author":"Lassmann","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_2","first-page":"87","article-title":"Biological markers in multiple sclerosis","volume":"11","author":"Franciotta","year":"2004","journal-title":"Int. MS J."},{"key":"ref_3","first-page":"1308","article-title":"Neurofilament light chain as a biomarker for diagnosis of multiple sclerosis","volume":"20","author":"Kouchaki","year":"2021","journal-title":"EXCLI J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1474-4422(22)00289-7","article-title":"Time for a new mechanism-driven framework to define multiple sclerosis progression","volume":"22","author":"Kuhlmann","year":"2022","journal-title":"Lancet Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Yang, J., Hamade, M., Wu, Q., Wang, Q., Axtell, R., Giri, S., and Mao-Draayer, Y. (2022). Current and Future Biomarkers in Multiple Sclerosis. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23115877"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Costa, J., Macaron, G., and Khaled, K.J.A. (2023). Biomarkers in multiple sclerosis: An update. Biomark. Neuropsychiatry, 9.","DOI":"10.1016\/j.bionps.2023.100075"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1155\/2006\/602103","article-title":"Biomarkers in Multiple Sclerosis: Role of Antibodies","volume":"22","author":"Berger","year":"2006","journal-title":"Dis. Markers"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1177\/1352458512443092","article-title":"Neurofilaments as biomarkers in multiple sclerosis","volume":"18","author":"Teunissen","year":"2012","journal-title":"Mult. Scler. J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1177\/1352458513488232","article-title":"Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis","volume":"19","author":"Teunissen","year":"2013","journal-title":"Mult. Scler. J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","article-title":"Neurofilaments as biomarkers in neurological disorders","volume":"14","author":"Khalil","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1161\/STROKEAHA.119.026410","article-title":"NfL (Neurofilament Light Chain) Levels as a Predictive Marker for Long-Term Outcome After Ischemic Stroke","volume":"50","author":"Uphaus","year":"2019","journal-title":"Stroke"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1001\/jamaneurol.2018.3223","article-title":"Serum Neurofilament Light Chain for Prognosis of Outcome after Cardiac Arrest","volume":"76","author":"Mattsson","year":"2019","journal-title":"JAMA Neurol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1002\/jnr.21803","article-title":"Validation of a novel biomarker for acute axonal injury in experimental autoimmune encephalomyelitis","volume":"86","author":"Gresle","year":"2008","journal-title":"J. Neurosci. Res."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Yuan, A., Rao, M.V., Veeranna, N.R., and Nixon, R.A. (2017). Neurofilaments and Neurofilament Proteins in Health and Disease. Cold Spring Harb. Perspect. Biol., 9.","DOI":"10.1101\/cshperspect.a018309"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1093\/brain\/awab241","article-title":"The potential of serum neurofilament as biomarker for multiple sclerosis","volume":"144","author":"Bittner","year":"2021","journal-title":"Brain"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4560","DOI":"10.2174\/1381612825666191210154535","article-title":"Neurofilament Proteins as Prognostic Biomarkers in Neurological Disorders","volume":"25","author":"Lee","year":"2020","journal-title":"Curr. Pharm. Des."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1007\/s40120-023-00535-z","article-title":"Neurofilament Light Chain in Adult and Pediatric Multiple Sclerosis: A Promising Biomarker to Better Characterize Disease Activity and Personalize MS Treatment","volume":"12","author":"Ghezzi","year":"2023","journal-title":"Neurol. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","article-title":"Neurofilament light chain as a biomarker in neurological disorders","volume":"90","author":"Gaetani","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e1007","DOI":"10.1212\/WNL.0000000000007032","article-title":"Blood neurofilament light chain as a biomarker of MS disease activity and treatment response","volume":"92","author":"Kuhle","year":"2019","journal-title":"Neurology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1001\/jamaneurol.2019.1534","article-title":"Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis","volume":"76","author":"Bridel","year":"2019","journal-title":"JAMA Neurol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Delaby, C., Bousiges, O., Bouvier, D., Fill\u00e9e, C., Fourier, A., Mond\u00e9sert, E., Nezry, N., Omar, S., Quadrio, I., and Rucheton, B. (2022). Neurofilaments contribution in clinic: State of the art. Front. Aging Neurosci., 14.","DOI":"10.3389\/fnagi.2022.1034684"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jim.2009.09.014","article-title":"Neurofilament ELISA validation","volume":"352","author":"Petzold","year":"2010","journal-title":"J. Immunol. Methods"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1177\/2211068215589580","article-title":"The Simoa HD-1 Analyzer: A Novel Fully Automated Digital Immunoassay Analyzer with Single-Molecule Sensitivity and Multiplexing","volume":"21","author":"Wilson","year":"2016","journal-title":"J. Lab. Autom."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1515\/cclm-2015-1195","article-title":"Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa","volume":"54","author":"Kuhle","year":"2016","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e1164","DOI":"10.1212\/NXI.0000000000001164","article-title":"Role of Chitinase 3-like 1 as a Biomarker in Multiple Sclerosis: A Systematic Review and Meta-analysis","volume":"9","author":"Floro","year":"2022","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Jatczak-Pawlik, I., Jurewicz, A., Domowicz, M., Ewiak-Paszy\u0144ska, A., and Stasio\u0142ek, M. (2024). CHI3L1 in Multiple Sclerosis\u2014From Bench to Clinic. Cells, 13.","DOI":"10.3390\/cells13242086"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s12035-022-03060-6","article-title":"CSF CXCL13 and Chitinase 3-like-1 Levels Predict Disease Course in Relapsing Multiple Sclerosis","volume":"60","author":"Lucchini","year":"2023","journal-title":"Mol. Neurobiol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Hrabar, D., Bakula, D., Vrkljan, N., Ratkajec, V., Glavcic, G., Miler, M., Pelajic, S., Rogic, D., Blazevic, N., and Pavic, T. (2023). YKL-40 as a biomarker in various inflammatory diseases: A review. Biochem. Medica, 34.","DOI":"10.11613\/BM.2024.010502"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1007\/s10072-023-06764-2","article-title":"Chitinase-3-like 1-protein in CSF: A novel biomarker for progression in patients with multiple sclerosis","volume":"44","author":"Talaat","year":"2023","journal-title":"Neurol. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"101856","DOI":"10.1016\/j.rechem.2024.101856","article-title":"A novel sandwich ELISA method for quantifying CHI3L1 in blood serum and cerebrospinal fluid multiple sclerosis patients using sustainable photo-irradiated zero-valence gold nanoparticles","volume":"11","author":"Mohammed","year":"2024","journal-title":"Results Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e972","DOI":"10.1212\/NXI.0000000000000972","article-title":"Potential Role of CHI3L1+ Astrocytes in Progression in MS","volume":"8","author":"Tarazona","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ana.20703","article-title":"Diagnostic criteria for multiple sclerosis: 2005 Revisions to the \u2018McDonald Criteria\u2019","volume":"58","author":"Polman","year":"2005","journal-title":"Ann. Neurol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"103366","DOI":"10.1016\/j.msard.2021.103366","article-title":"Serum neurofilament light chain correlates with myelin and axonal magnetic resonance imaging markers in multiple sclerosis","volume":"57","author":"Yik","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e1154","DOI":"10.1212\/NXI.0000000000001154","article-title":"Neurofilament Light Chain Levels in Multiple Sclerosis Correlate With Lesions Containing Foamy Macrophages and With Acute Axonal Damage","volume":"9","author":"Bosch","year":"2022","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1177\/13524585211039104","article-title":"Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based study","volume":"28","author":"Rosenstein","year":"2021","journal-title":"Mult. Scler. J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e1201","DOI":"10.1212\/WNL.0000000000009097","article-title":"Blood neurofilament light levels segregate treatment effects in multiple sclerosis","volume":"94","author":"Delcoigne","year":"2020","journal-title":"Neurology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1474-4422(22)00009-6","article-title":"Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: A retrospective modelling and validation study","volume":"21","author":"Benkert","year":"2022","journal-title":"Lancet Neurol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1136\/jnnp.2004.043315","article-title":"Axonal damage accumulates in the progressive phase of multiple sclerosis: Three year follow up study","volume":"76","author":"Petzold","year":"2005","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_41","first-page":"255","article-title":"Phosphorylated neurofilament heavy chain (pNFH) in clinically isolated syndrome and multiple sclerosis","volume":"58","year":"2021","journal-title":"Noro Psikiyatr. Arsivi"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/13524585241311212","article-title":"Neurofilament heavy chain in secondary progressive multiple sclerosis","volume":"31","author":"Ammoscato","year":"2025","journal-title":"Mult. Scler. J."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Gil-Perotin, S., Castillo-Villalba, J., Cubas-Nu\u00f1ez, L., Gasque, R., Hervas, D., Gomez-Mateu, J., Alcala, C., Perez-Miralles, F., Gascon, F., and Dominguez, J.A. (2019). Combined Cerebrospinal Fluid Neurofilament Light Chain Protein and Chitinase-3 Like-1 Levels in Defining Disease Course and Prognosis in Multiple Sclerosis. Front. Neurol., 10.","DOI":"10.3389\/fneur.2019.01008"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Ahmad, I., Wergeland, S., Oveland, E., and B\u00f8, L. (2023). An Association of Chitinase-3 Like-Protein-1 With Neuronal Deterioration in Multiple Sclerosis. ASN Neuro, 15.","DOI":"10.1177\/17590914231198980"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1177\/1352458518794308","article-title":"Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis","volume":"25","author":"Sellebjerg","year":"2018","journal-title":"Mult. Scler. J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"101009","DOI":"10.1016\/j.lanepe.2024.101009","article-title":"Fluid biomarkers in multiple sclerosis: From current to future applications","volume":"44","author":"Gaetani","year":"2024","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1177\/1352458519871818","article-title":"Can CSF biomarkers predict future MS disease activity and severity?","volume":"26","author":"Magliozzi","year":"2020","journal-title":"Mult. Scler. J."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/13\/6\/1394\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:47:28Z","timestamp":1760032048000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/13\/6\/1394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":47,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["biomedicines13061394"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines13061394","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,6]]}}}